Jack Allen
Stock Analyst at Baird
(0.77)
# 3,633
Out of 4,814 analysts
42
Total ratings
32.35%
Success rate
-21.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.20 | +400.00% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $7.27 | +450.21% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $0.65 | +2,053.85% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $61.99 | +71.00% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $7.27 | +147.76% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $15.46 | +1,064.67% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $140 → $120 | $4.15 | +2,791.57% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.31 | +247.07% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $37.76 | +37.71% | 2 | May 9, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $28.54 | +194.32% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $1.25 | +540.00% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $1.45 | +727.59% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.42 | +1,103.37% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $1.12 | +2,400.00% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.43 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.16 | +185.26% | 1 | Oct 7, 2021 |
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.20
Upside: +400.00%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $7.27
Upside: +450.21%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $0.65
Upside: +2,053.85%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $61.99
Upside: +71.00%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $7.27
Upside: +147.76%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $15.46
Upside: +1,064.67%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $140 → $120
Current: $4.15
Upside: +2,791.57%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.31
Upside: +247.07%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $37.76
Upside: +37.71%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $28.54
Upside: +194.32%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $1.25
Upside: +540.00%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $1.45
Upside: +727.59%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.42
Upside: +1,103.37%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $1.12
Upside: +2,400.00%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.43
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.16
Upside: +185.26%